Daniel M. Geynisman

Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Timothy D. Gilligan, Daniel W. Lin, Rahul Aggarwal et al. · Journal of the National Comprehensive Cancer Network · 2019 · 440 citations

Surgical Oncology, Cancer Management, Gynecology +17

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

Joaquim Bellmunt, Maha Hussain, Jürgen E. Gschwend et al. · The Lancet Oncology · 2021 · 393 citations · Full text

Urology, Versus Observation, Genitourinary Cancer +6

Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study

Nieves Martínez Chanzá, Wanling Xie, Mehmet Asım Bilen et al. · The Lancet Oncology · 2019 · 173 citations

Urology, Genitourinary Cancer, Kidney Research +8

Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011

Ya‐Chen Tina Shih, Fabrice Smieliauskas, Daniel M. Geynisman et al. · Journal of Clinical Oncology · 2015 · 157 citations · Full text

Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

Peter H. O’Donnell, Matthew I. Milowsky, Daniel P. Petrylak et al. · Journal of Clinical Oncology · 2023 · 157 citations · Full text